Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AKAN vs NEXR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NEXR Captures Overall Composite Edge (31.0 SELL vs 43.8 HOLD), While AKAN Leads 4–1 on Growth & Valuation Pillars

NEXR Overall Winner 6-Pillar Tally: AKAN 4 – 1 NEXR (1 Tie) Matrix Metrics: AKAN 7 – 1 NEXR

As of Nov 16, 2026, NEXR (NEXR) captures the overall head-to-head institutional edge over Akanda Corp. Common Shares (AKAN) on higher Unified Composite conviction (31.0/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while AKAN wins 4–1 across the 6-pillar growth and valuation breakdown. AKAN trades at $2.00 (N/M Forward P/E, -1254.5% operating margin) versus NEXR at $1.38 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While AKAN currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. NEXR 31.0/100 SELL), NEXR captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (N/A vs. -1254.5% operating margin) and revenue trajectory (N/A vs. +21.9% YoY).
  • Technical & Structure Timing Caution: AKAN is currently in a Breakdown options structure phase (RSI 66.4); meanwhile NEXR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 54.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKAN vs NEXR
AKAN NASDAQ
Akanda Corp. Common Shares
Medicinal Chemicals & Botanical Products
$2.00
+47.05% 1D
Market Cap $2.2M
TTM Revenue $662,469
Forward P/E N/M
Beta / 30D Vol 5.43β · 428% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 20.0 Fund 60.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 66
RSI-14: 66.4 · SMA20: $1.04 · SMA50: $1.86
NEXR US Equity Head-to-Head Winner
NEXR
Institutional Equity
$1.38
-7.38% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 8.42β · 2730% Vol
Unified Composite Score
31.0 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.5 · SMA20: $0.93 · SMA50: $1.16

6-Pillar Scorecard Institutional Category Breakdown (AKAN 4 – 1 NEXR)

Columns: Metric · AKAN · NEXR
1. Valuation Multiples AKAN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.3x N/M
2. Growth & Scale AKAN
Revenue Growth (YoY) +21.9% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $662,469 N/A
Market Cap $2.2M N/A
3. Profitability & Quality AKAN
Gross Margin -12.0% N/A
Operating Margin -1254.5% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -60.9% N/A
4. Balance Sheet & Cash Flow AKAN
Cash Generation (TTM) -$7.9M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage -60.9% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NEXR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKAN (7) vs NEXR (1)
Institutional Metric AKAN NEXR Criterion Row Edge
Market Capitalization
Scale
$2.2M N/A Larger Scale AKAN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+21.9% N/A Higher Growth AKAN
Operating Margin (TTM)
Profitability
-1254.5% N/A Higher Margin AKAN
Net Profit Margin
Profitability
0.0% N/A Higher Margin AKAN
Return on Equity (ROE)
Capital Efficiency
-60.9% N/A Higher ROE AKAN
52-Week Range Position
Momentum
2% ($0–$79) 23% ($0–$5) Stronger Trend NEXR
Beta / 30D Volatility
Risk Regime
5.43β · 428% Vol 8.42β · 2730% Vol Lower Realized Risk AKAN
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 31.0 / 100 (SELL) Higher Composite AKAN
Trailing 12M Revenue (USD)
Operating Scale
$662,469 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-12.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.9M EBITDA (-60.9% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NEXR +0.61 pp
AKAN: +66.66% · NEXR: +67.27%
3M Horizon NEXR +11.12 pp
AKAN: -58.85% · NEXR: -47.73%
6M Horizon NEXR +88.46 pp
AKAN: -87.73% · NEXR: +0.73%
1Y Horizon AKAN +225.77 pp
AKAN: +186.56% · NEXR: -39.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKAN vs NEXR. Trailing 12-month operating profitability (AKAN -1254.5% vs NEXR N/A) and valuation multiples (AKAN N/M vs NEXR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AKAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$662,469
Gross Margin-12.0%
Op. Margin-1254.5%
ROE / Fwd P/E-60.9% · N/M
NEXR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKAN BREAKDOWN
137d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact AKAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NEXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NEXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKAN Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.2M market capitalization and -1254.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NEXR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AKAN vs NEXR Key Questions & Quantitative Answers

As of Nov 16, 2026, NEXR (NEXR) captures the overall head-to-head institutional edge over Akanda Corp. Common Shares (AKAN) on higher Unified Composite conviction (31.0/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while AKAN wins 4–1 across the 6-pillar growth and valuation breakdown. AKAN trades at $2.00 (N/M Forward P/E, -1254.5% operating margin) versus NEXR at $1.38 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While AKAN currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. NEXR 31.0/100 SELL), NEXR captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (N/A vs. -1254.5% operating margin) and revenue trajectory (N/A vs. +21.9% YoY). Technical & Structure Timing Caution: AKAN is currently in a Breakdown options structure phase (RSI 66.4); meanwhile NEXR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 54.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AKAN leads the Growth & Scale pillar: AKAN posts +21.9% YoY revenue growth and +0.0% YoY earnings growth on $662,469 TTM revenue (-12.0% gross margin, -1254.5% operating margin), compared with NEXR at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AKAN generates $662,469 in USD-normalized revenue versus N/A for NEXR. In operating R&D and SG&A reinvestment, AKAN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NEXR.

AKAN screens cheaper on headline valuation multiples. AKAN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (unreported EBITDA margin), whereas NEXR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKAN (-60.9% ROE) versus NEXR (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, AKAN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (5.43β · 428% Vol realized risk). By comparison, NEXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.42β · 2730% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.